These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1162 related items for PubMed ID: 9743345

  • 1. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A, Nguyen P, Finkelman F, Elkon KB, Via CS.
    J Immunol; 1998 Sep 15; 161(6):2848-55. PubMed ID: 9743345
    [Abstract] [Full Text] [Related]

  • 2. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand.
    Miura Y, Thoburn CJ, Bright EC, Hess AD.
    Biol Blood Marrow Transplant; 2004 Mar 15; 10(3):156-70. PubMed ID: 14993881
    [Abstract] [Full Text] [Related]

  • 3. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells.
    Rus V, Svetic A, Nguyen P, Gause WC, Via CS.
    J Immunol; 1995 Sep 01; 155(5):2396-406. PubMed ID: 7650373
    [Abstract] [Full Text] [Related]

  • 4. MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways.
    Benihoud K, Bonardelle D, Bobé P, Kiger N.
    Eur J Immunol; 1997 Feb 01; 27(2):415-20. PubMed ID: 9045912
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD.
    Lee S, Chong SY, Lee JW, Kim SC, Min YH, Hahn JS, Ko YW.
    Bone Marrow Transplant; 1997 Nov 01; 20(10):883-8. PubMed ID: 9404931
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z, Shatry A, Deyev V, Podack E, Mammolenti M, Blazar BR, Yagita H, Levy RB.
    Biol Blood Marrow Transplant; 2005 Aug 01; 11(8):576-86. PubMed ID: 16041307
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of graft-versus-host disease (GVHD) on host hematopoietic progenitor cells is mediated by Fas-Fas ligand interactions but this does not explain the effect of GVHD on donor cells.
    Iwasaki T, Hamano T, Saheki K, Kuroiwa T, Kataoka Y, Takemoto Y, Ogata A, Sugihara A, Terada N, Fujimoto J, Kakishita E.
    Cell Immunol; 1999 Oct 10; 197(1):30-8. PubMed ID: 10555993
    [Abstract] [Full Text] [Related]

  • 15. The Fas death pathway controls coordinated expansions of type 1 CD8 and type 2 CD4 T cells in Trypanosoma cruzi infection.
    Guillermo LV, Silva EM, Ribeiro-Gomes FL, De Meis J, Pereira WF, Yagita H, DosReis GA, Lopes MF.
    J Leukoc Biol; 2007 Apr 10; 81(4):942-51. PubMed ID: 17261545
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones.
    Esser MT, Dinglasan RD, Krishnamurthy B, Gullo CA, Graham MB, Braciale VL.
    J Immunol; 1997 Jun 15; 158(12):5612-8. PubMed ID: 9190908
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.